Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (96159)	11/15/2001 5:40:36 PM
From: Jim Bishop	Respond to of 150070

HYRB HyperBaric Systems Validates Platelet Preservation Technology PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 15, 2001--HyperBaric Systems (OTCBB:HYRB - news) has achieved successful confirmation of its proprietary blood platelet preservation technology and is continuing its groundbreaking experiments at The Center for Blood Research in Sacramento. Dr. David Lucas, Scientific Director for HyperBaric, had previously announced that experiments at its laboratory in Russia had demonstrated successful platelet function after ten days of cold storage. ``So far we have replicated our experiments in Sacramento for eight days and confirmed results achieved in Russia,'' he said. ``During the period when experiments in Sacramento were being conducted, we attained additional significant improvements in Russia that we want to implement as soon as possible.'' Dr. Lucas noted that, ``The majority of decay in platelets under refrigerated conditions takes place within the first 24 hours then becomes minimal thereafter. We have just recently discovered a significant enhancement to our cold-temperature technology that dramatically reduces the initial impact of cooling on the platelets. This is another very important achievement in the ongoing refinement of our platelet preservation technology.'' ``We want to continue our experiments at The Center for Blood Research, implementing our new findings, and attain preservation periods exceeding ten days,'' Dr. Lucas stated. ``Our attention is now focused on these exciting new improvements and making arrangements with regulatory authorities to move forward with human infusion clinical studies.'' Before HyperBaric's breakthrough technology, experiments to store blood platelets in refrigerated conditions were attempted for more than forty years without success. ``In less than four years we have accomplished major achievements in the field of blood platelet preservation, what others have not done in the past forty years. This is just the beginning,'' Harry Masuda, HyperBaric President said. ``I believe our technology is going to save millions of dollars for blood banks, hospitals and medical centers. More importantly I believe we will save thousands of lives worldwide,'' he added. Blood platelets, the congealing component of blood, are essential for use in patients undergoing chemotherapy treatments, organ transplants and major surgery. ``Currently, nearly half of the world's population has no access to blood platelets, primarily due to logistics created by their very limited shelf life,'' Bob Strom Vice President of Sales and Marketing said. ``Our extended preservation technology will allow the shipping of platelets to any global point and make inventory control a much easier task for the agencies involved.'' The new proprietary technology from HyperBaric Systems also helps solve the problem of bacterial damage to blood platelets by virtually halting all pathogen growth. Bacterial growth during room temperature storage is considered to be one of the major dilemmas of platelet use. ``We don't create any additional costs in eliminating bacterial problems, because it is a natural result of our cold temperature technology,'' Dr. Lucas said. HyperBaric Systems is headquartered in Palo Alto, California, with additional offices in the greater San Francisco Bay area and Rancho Mirage, California. The company also has research and testing facilities in Russia and Michigan. Certain statements contained herein are ``forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to the future results of research and development of the Company's products, the ability or inability to replicate test results, the ability to successfully commercialize the Company's products, and other risk factors discussed in filings made by the Company with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Contact: HyperBaric Systems Harry Masuda, 650/323-0943 E-mail: hmasuda@california.com or HyperBaric Systems Bob Strom, 760/346-2698 E-mail: restrom3@cs.com or Yes International Rich Kaiser, 800/631-8127 E-mail: rich@yesinternational.com or Wall Street Marketing Mark Taggatz, 949/477-0640 E-mail: wsmg@earthlink.net or Intermark Bobbi Cowan, 818/346-1975 E-mail: bcowanintermark@msn.com

To: SSP who wrote (96159)	11/15/2001 5:42:38 PM
From: Jim Bishop	Read Replies (2) \| Respond to of 150070

ENDV Endovasc Announces U.S. Patent Office Notification for Resorbable Biodegradable Stent MONTGOMERY, Texas--(BW HealthWire)--Nov. 15, 2001--Endovasc Ltd. Inc. announced today the U.S. Patent Office (USPTO) has sent the company notification of allowable claims on the company's continuation-in-part of its previous stent patent, U.S. Patent 5,980,551 issued Nov. 9, 1999 for a Totally Resorbable Biodegradable Stent. ``This second patent greatly strengthens our Company's intellectual property built around this technology,'' said the inventor and CEO of Endovasc, Dr. David P. Summers. ``We have three prior stent patents which mention, either in text or in claims, a biodegradable stent with the earliest citation going back to a 1992 filing date.'' The Company's resorbable prosthesis (stent) is a unique concept in the medical device market. There are no stent products currently on the market which will totally degrade by natural biological processes leaving the vessel or organ totally free from any prosthetic remains. The resorbable prosthesis maintains strength needed to acutely open and maintain a vessel, duct, tract or organ confirmation and also precise chronicity controlling the release and delivery of drugs or biologic agents providing a medicinal therapy. The multi-billion dollar market for medical devices continues to grow, with the top three medical device manufacturers reporting worldwide stent sales during 2000 at over a billion dollars. About Endovasc Ltd. Inc. Endovasc Ltd. Inc. is a biopharmaceutical biotech company pioneering drug delivery technology. The Company's products and processes, which include Liprostin(TM) (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, an angiogenic agent), PROSTENT(TM) stent-coating technology, and a biodegradable resorbable prosthesis are covered by patents, license and trade secrets for competing in a multi-billion dollar market. The foregoing statements are made under the ``Safe Harbor'' Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact: -------------------------------------------------------------------------------- Contact: Endovasc Ltd. Inc., Montgomery New Business Development and Investor Relations: John (Jack) T. Sorbi, 936/448-2222 Fax: 936/582-2250 jack@endovasc.com www.endovasc.com